The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 01 2019
Historique:
received: 22 05 2018
accepted: 23 11 2018
entrez: 19 1 2019
pubmed: 19 1 2019
medline: 1 5 2020
Statut: epublish

Résumé

Resistance to 5-Fluorouracil chemotherapy is a major cause of therapeutic failure in colon cancer cure. Development of combined therapies constitutes an effective strategy to inhibit cancer cells and prevent the emergence of drug resistance. For this purpose, we investigated the anti-tumoral effect of thirteen phenolic compounds, from the Tunisian quince Cydonia oblonga Miller, alone or combined to 5-FU, on the human 5-FU-resistant LS174-R colon cancer cells in comparison to parental cells. Our results showed that only Kaempferol was able to chemo-sensitize 5-FU-resistant LS174-R cells. This phenolic compound combined with 5-FU exerted synergistic inhibitory effect on cell viability. This combination enhanced the apoptosis and induced cell cycle arrest of both chemo-resistant and sensitive cells through impacting the expression levels of different cellular effectors. Kaempferol also blocked the production of reactive oxygen species (ROS) and modulated the expression of JAK/STAT3, MAPK, PI3K/AKT and NF-κB. In silico docking analysis suggested that the potent anti-tumoral effect of Kaempferol, compared to its two analogs (Kaempferol 3-O-glucoside and Kampferol 3-O-rutinoside), can be explained by the absence of glucosyl groups. Overall, our data propose Kaempferol as a potential chemotherapeutic agent to be used alone or in combination with 5-FU to overcome colon cancer drug resistance.

Identifiants

pubmed: 30655588
doi: 10.1038/s41598-018-36808-z
pii: 10.1038/s41598-018-36808-z
pmc: PMC6336835
doi:

Substances chimiques

Antineoplastic Agents 0
Kaempferols 0
Phenols 0
Fluorouracil U3P01618RT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

195

Références

J Biol Chem. 2001 Apr 27;276(17):14170-7
pubmed: 11278511
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Int J Cancer. 2002 Apr 1;98(4):498-504
pubmed: 11920608
J Med Chem. 2005 Feb 10;48(3):737-43
pubmed: 15689157
J Cell Physiol. 2005 Sep;204(3):927-33
pubmed: 15795936
Nucleic Acids Res. 2007 Jan;35(Database issue):D198-201
pubmed: 17145705
Mol Cancer Ther. 2007 Jan;6(1):163-72
pubmed: 17218638
Anticancer Res. 2008 Jan-Feb;28(1A):9-14
pubmed: 18383818
Molecules. 2008 Aug 05;13(8):1551-69
pubmed: 18794772
Cancer Res. 2009 Mar 1;69(5):1951-7
pubmed: 19244128
J Chem Inf Model. 2009 Jun;49(6):1535-46
pubmed: 19453150
Biopharm Drug Dispos. 2009 Oct;30(7):356-65
pubmed: 19722166
Front Biosci (Elite Ed). 2010 Jan 01;2:241-9
pubmed: 20036874
BMC Cancer. 2010 Aug 13;10:425
pubmed: 20704765
Future Oncol. 2010 Sep;6(9):1461-78
pubmed: 20919829
Chembiochem. 2010 Dec 10;11(18):2579-88
pubmed: 21108268
Clin Med Oncol. 2008;2:27-35
pubmed: 21892263
Cancer Cell. 2011 Nov 15;20(5):620-34
pubmed: 22094256
Antioxid Redox Signal. 2012 Jun 1;16(11):1295-322
pubmed: 22117137
Cell. 2012 Jun 8;149(6):1269-83
pubmed: 22682249
Food Chem. 2013 Jan 15;136(2):636-42
pubmed: 23122108
Nucleic Acids Res. 2013 Jan;41(Database issue):D1228-33
pubmed: 23180781
Food Chem. 2013 Jun 15;138(4):2099-107
pubmed: 23497863
J Cell Sci. 2013 Jan 15;126(Pt 2):393-401
pubmed: 23525005
Nat Rev Mol Cell Biol. 2013 May;14(5):297-306
pubmed: 23594950
PLoS One. 2013 Jun 10;8(6):e64961
pubmed: 23762272
PLoS One. 2013 Oct 07;8(10):e76693
pubmed: 24116137
Clin Cancer Res. 2014 Feb 15;20(4):837-46
pubmed: 24323901
Cell Death Dis. 2014 Jan 09;5:e983
pubmed: 24407236
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W167-74
pubmed: 24861621
Anticancer Res. 2014 Jun;34(6):2907-11
pubmed: 24922653
Biomed Res Int. 2014;2014:150845
pubmed: 25013758
World J Gastroenterol. 2014 Aug 7;20(29):9744-58
pubmed: 25110412
BMC Cancer. 2014 Aug 18;14:599
pubmed: 25134433
Pharmacogenomics J. 2015 Apr;15(2):135-43
pubmed: 25179828
Molecules. 2014 Sep 04;19(9):13848-77
pubmed: 25191874
Cancers (Basel). 2014 Sep 05;6(3):1769-92
pubmed: 25198391
World J Biol Chem. 2014 Aug 26;5(3):346-54
pubmed: 25225602
Mol Cancer Ther. 2014 Nov;13(11):2713-26
pubmed: 25249558
Contemp Oncol (Pozn). 2014;18(4):222-6
pubmed: 25258577
Semin Cancer Biol. 2015 Dec;35 Suppl:S224-S243
pubmed: 25600295
PLoS One. 2015 Feb 11;10(2):e0115686
pubmed: 25671635
Food Funct. 2015 May;6(5):1460-9
pubmed: 25857357
BMC Cancer. 2015 Mar 21;15:156
pubmed: 25884995
Cancer Cell Int. 2015 Apr 24;15:46
pubmed: 26074733
Int J Colorectal Dis. 2015 Oct;30(10):1305-10
pubmed: 26099322
Chemotherapy (Los Angel). 2014 Dec;3(3):null
pubmed: 26161298
Toxicol Res. 2015 Jun;31(2):151-6
pubmed: 26191381
BMC Cancer. 2015 Aug 11;15:581
pubmed: 26260159
Nat Commun. 2015 Aug 13;6:7972
pubmed: 26268986
Int J Mol Med. 2015 Oct;36(4):957-66
pubmed: 26310353
World J Gastroenterol. 2015 Nov 7;21(41):11777-92
pubmed: 26557002
Ther Adv Med Oncol. 2016 Jan;8(1):57-84
pubmed: 26753006
Tumour Biol. 2016 Jul;37(7):9465-72
pubmed: 26787540
Cancer Cell Int. 2016 Feb 02;16:1
pubmed: 26839513
Chin Med J (Engl). 2016 Feb 20;129(4):456-63
pubmed: 26879020
Oncol Lett. 2016 Feb;11(2):1043-1050
pubmed: 26893688
Cell Death Dis. 2016 Feb 25;7:e2111
pubmed: 26913603
Biochim Biophys Acta. 2016 Apr;1865(2):255-65
pubmed: 26993403
Cells. 2016 Apr 06;5(2):null
pubmed: 27058560
Anticancer Res. 2016 Apr;36(4):1631-9
pubmed: 27069140
Sci Rep. 2016 Apr 19;6:24675
pubmed: 27091625
Nutr Cancer. 2016 Aug-Sep;68(6):879-91
pubmed: 27366999
Biomol Ther (Seoul). 2016 Nov 1;24(6):604-609
pubmed: 27469143
World J Gastrointest Oncol. 2016 Jul 15;8(7):532-42
pubmed: 27559432
Oncol Lett. 2016 Sep;12(3):1994-2000
pubmed: 27602127
Nutrients. 2016 Sep 21;8(9):null
pubmed: 27657126
Int J Oncol. 2016 Dec;49(6):2558-2568
pubmed: 27748801
Anticancer Res. 2016 Nov;36(11):5639-5647
pubmed: 27793885
Cell Physiol Biochem. 2016;40(1-2):62-76
pubmed: 27842308
Oncol Lett. 2016 Nov;12(5):3586-3590
pubmed: 27900040
PLoS One. 2016 Dec 9;11(12):e0167491
pubmed: 27936162
Onco Targets Ther. 2016 Dec 05;9:7373-7384
pubmed: 27980427
Nutrients. 2016 Dec 14;8(12):
pubmed: 27983622
Int J Mol Sci. 2017 Jan 19;18(1):
pubmed: 28106826
Oncotarget. 2017 Mar 7;8(10):17216-17228
pubmed: 28212547
Neoplasia. 2017 Apr;19(4):301-309
pubmed: 28284059
Int J Mol Sci. 2017 Mar 17;18(3):
pubmed: 28304343
Tumour Biol. 2017 Apr;39(4):1010428317697553
pubmed: 28381160
Tumour Biol. 2017 May;39(5):1010428317698368
pubmed: 28459196
Nucleic Acids Res. 2017 Jul 3;45(W1):W356-W360
pubmed: 28472422
Am J Cancer Res. 2017 Jul 01;7(7):1588-1605
pubmed: 28744407
J Cancer. 2017 Jul 21;8(12):2319-2327
pubmed: 28819436
Sci Rep. 2018 Jan 18;8(1):1151
pubmed: 29348601
Clin Gastroenterol Hepatol. 2018 Jul 26;:null
pubmed: 30056182
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Ichrak Riahi-Chebbi (I)

Institut Pasteur de Tunis, LR11IPT04/LR16IPT04 Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale appliquées aux Maladies infectieuses, 1002, Tunis, Tunisia.
Université de Tunis El Manar, 1068, Tunis, Tunisia.

Soumaya Souid (S)

Institut Pasteur de Tunis, LR11IPT04/LR16IPT04 Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale appliquées aux Maladies infectieuses, 1002, Tunis, Tunisia.
Université de Tunis El Manar, 1068, Tunis, Tunisia.

Houcemeddine Othman (H)

Institut Pasteur de Tunis, LR11IPT08/LR16IPT08 Laboratoire des Venins et Biomolécules thérapeutiques, 1002, Tunis, Tunisia.
Université de Tunis El Manar, 1068, Tunis, Tunisia.

Meriam Haoues (M)

Institut Pasteur de Tunis, LR11IPT02/ LR16IPT02 Laboratoire de Recherche sur la Transmission, le Contrôle et l'Immunobiologie des Infections, 1002, Tunis, Tunisia.
Université de Tunis El Manar, 1068, Tunis, Tunisia.

Habib Karoui (H)

Institut Pasteur de Tunis, LR11IPT04/LR16IPT04 Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale appliquées aux Maladies infectieuses, 1002, Tunis, Tunisia.
Université de Tunis El Manar, 1068, Tunis, Tunisia.

Alain Morel (A)

CRCINA, INSERM U892, Université de Nantes, Université d'Angers, Paul Papin ICO cancer center, Angers, France.

Najet Srairi-Abid (N)

Institut Pasteur de Tunis, LR11IPT08/LR16IPT08 Laboratoire des Venins et Biomolécules thérapeutiques, 1002, Tunis, Tunisia.
Université de Tunis El Manar, 1068, Tunis, Tunisia.

Makram Essafi (M)

Institut Pasteur de Tunis, LR11IPT02/ LR16IPT02 Laboratoire de Recherche sur la Transmission, le Contrôle et l'Immunobiologie des Infections, 1002, Tunis, Tunisia.
Université de Tunis El Manar, 1068, Tunis, Tunisia.

Khadija Essafi-Benkhadir (K)

Institut Pasteur de Tunis, LR11IPT04/LR16IPT04 Laboratoire d'Epidémiologie Moléculaire et de Pathologie Expérimentale appliquées aux Maladies infectieuses, 1002, Tunis, Tunisia. essafi.khadija@pasteur.rns.tn.
Université de Tunis El Manar, 1068, Tunis, Tunisia. essafi.khadija@pasteur.rns.tn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH